secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2026-06-12T20:55:55+00:00
Accession:  0001193125-26-269635
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Priced 8,933,334 shares at $37.50/share and 1,733,333 pre-funded warrants at $37.499 each.
- Gross proceeds ~$400M; net proceeds ~$376M (or ~$432.4M if underwriters' option fully exercised).
- Underwriters granted 30-day option to purchase up to 1,600,000 additional shares.
- Offering expected to close June 15, 2026; joint book-runners: Jefferies, Goldman Sachs, Morgan Stanley, Barclays.
- Net proceeds for general corporate purposes and pipeline advancement (no specific allocation disclosed).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/0001193125-26-269635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/d152122d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-269635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer